VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Monday, December 29, 2025
Stock Comparison
Novo Nordisk A/S vs Roche Holding AG
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Novo Nordisk A/S
NOVOB · Nasdaq Copenhagen
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.
View NOVOB analysisRoche Holding AG
ROG · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Roche Holding AG's moat claims, evidence, and risks.
View ROG analysisComparison highlights
- Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 68 / 100 for Roche Holding AG).
- Segment focus: Novo Nordisk A/S has 3 segments (71.1% in Diabetes care); Roche Holding AG has 2 segments (76.3% in Pharmaceuticals).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
- Moat breadth: Novo Nordisk A/S has 5 moat types across 3 domains; Roche Holding AG has 5 across 3.
Primary market context
Novo Nordisk A/S
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
Global
Payers/providers and patients (via wholesalers/pharmacies/hospitals)
Originator pharma (R&D, regulatory, manufacturing, commercialization)
71.1%
Roche Holding AG
Pharmaceuticals
Innovative (branded) prescription pharmaceuticals
Global
Healthcare providers and systems (hospitals/clinics), payers/governments, and patients
Innovator pharmaceutical developer, manufacturer and marketer
76.3%
Side-by-side metrics
Moat coverage
Shared moat types
Novo Nordisk A/S strengths
Roche Holding AG strengths
Segment mix
Novo Nordisk A/S segments
Full profile >Diabetes care
Oligopoly
Obesity care
Duopoly
Rare disease
Oligopoly
Roche Holding AG segments
Full profile >Pharmaceuticals
Competitive
Diagnostics
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.